Logo image of XGN

EXAGEN INC (XGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XGN - US30068X1037 - Common Stock

7.22 USD
-0.28 (-3.73%)
Last: 12/2/2025, 1:51:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XGN. XGN was compared to 534 industry peers in the Biotechnology industry. XGN has a bad profitability rating. Also its financial health evaluation is rather negative. XGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XGN has reported negative net income.
XGN had a negative operating cash flow in the past year.
XGN had negative earnings in each of the past 5 years.
In the past 5 years XGN always reported negative operating cash flow.
XGN Yearly Net Income VS EBIT VS OCF VS FCFXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.31%, XGN is in the better half of the industry, outperforming 67.42% of the companies in the same industry.
The Return On Equity of XGN (-104.97%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.31%
ROE -104.97%
ROIC N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
XGN Yearly ROA, ROE, ROICXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

With a decent Gross Margin value of 59.86%, XGN is doing good in the industry, outperforming 77.90% of the companies in the same industry.
In the last couple of years the Gross Margin of XGN has grown nicely.
XGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
XGN Yearly Profit, Operating, Gross MarginsXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
XGN has more shares outstanding than it did 1 year ago.
XGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XGN has a worse debt to assets ratio.
XGN Yearly Shares OutstandingXGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
XGN Yearly Total Debt VS Total AssetsXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.50, we must say that XGN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.50, XGN is in line with its industry, outperforming 44.94% of the companies in the same industry.
XGN has a Debt/Equity ratio of 1.35. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.35, XGN is not doing good in the industry: 78.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z -3.5
ROIC/WACCN/A
WACC8.66%
XGN Yearly LT Debt VS Equity VS FCFXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

XGN has a Current Ratio of 4.08. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
XGN has a Current ratio of 4.08. This is comparable to the rest of the industry: XGN outperforms 49.44% of its industry peers.
XGN has a Quick Ratio of 4.08. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.08, XGN perfoms like the industry average, outperforming 50.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
XGN Yearly Current Assets VS Current LiabilitesXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

XGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.74%.
XGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.08%.
Measured over the past years, XGN shows a small growth in Revenue. The Revenue has been growing by 6.62% on average per year.
EPS 1Y (TTM)5.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.71%
Revenue 1Y (TTM)14.08%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%37.87%

3.2 Future

XGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.70% yearly.
XGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.02% yearly.
EPS Next Y18.32%
EPS Next 2Y25.83%
EPS Next 3Y20.38%
EPS Next 5Y15.7%
Revenue Next Year21.08%
Revenue Next 2Y17.87%
Revenue Next 3Y15.12%
Revenue Next 5Y14.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XGN Yearly Revenue VS EstimatesXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
XGN Yearly EPS VS EstimatesXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XGN Price Earnings VS Forward Price EarningsXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XGN Per share dataXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

XGN's earnings are expected to grow with 20.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.83%
EPS Next 3Y20.38%

More info and screens

0

5. Dividend

5.1 Amount

XGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXAGEN INC

NASDAQ:XGN (12/2/2025, 1:51:02 PM)

7.22

-0.28 (-3.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners50.11%
Inst Owner Change-12.58%
Ins Owners3.39%
Ins Owner Change-3.17%
Market Cap163.61M
Revenue(TTM)63.60M
Net Income(TTM)-19.04M
Analysts83.33
Price Target15.74 (118.01%)
Short Float %4.84%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-60.42%
Min EPS beat(2)-94.88%
Max EPS beat(2)-25.97%
EPS beat(4)2
Avg EPS beat(4)-23.8%
Min EPS beat(4)-94.88%
Max EPS beat(4)23.84%
EPS beat(8)6
Avg EPS beat(8)5.06%
EPS beat(12)9
Avg EPS beat(12)11.35%
EPS beat(16)12
Avg EPS beat(16)9.72%
Revenue beat(2)2
Avg Revenue beat(2)2.77%
Min Revenue beat(2)1.05%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)2.17%
Min Revenue beat(4)-2.37%
Max Revenue beat(4)5.51%
Revenue beat(8)6
Avg Revenue beat(8)5.05%
Revenue beat(12)10
Avg Revenue beat(12)13.51%
Revenue beat(16)13
Avg Revenue beat(16)12.1%
PT rev (1m)31.71%
PT rev (3m)38.17%
EPS NQ rev (1m)-45.92%
EPS NQ rev (3m)-34.54%
EPS NY rev (1m)0%
EPS NY rev (3m)2.72%
Revenue NQ rev (1m)-3.03%
Revenue NQ rev (3m)-1.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.57
P/FCF N/A
P/OCF N/A
P/B 9.02
P/tB 9.02
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS2.81
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.31%
ROE -104.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.86%
FCFM N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
F-Score5
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.44%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z -3.5
F-Score5
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)115%
Cap/Depr(5y)136.67%
Cap/Sales(3y)3.99%
Cap/Sales(5y)3.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.71%
EPS Next Y18.32%
EPS Next 2Y25.83%
EPS Next 3Y20.38%
EPS Next 5Y15.7%
Revenue 1Y (TTM)14.08%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%37.87%
Revenue Next Year21.08%
Revenue Next 2Y17.87%
Revenue Next 3Y15.12%
Revenue Next 5Y14.02%
EBIT growth 1Y18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.05%
EBIT Next 3Y30.45%
EBIT Next 5Y23.85%
FCF growth 1Y62.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.09%
OCF growth 3YN/A
OCF growth 5YN/A

EXAGEN INC / XGN FAQ

Can you provide the ChartMill fundamental rating for EXAGEN INC?

ChartMill assigns a fundamental rating of 2 / 10 to XGN.


What is the valuation status of EXAGEN INC (XGN) stock?

ChartMill assigns a valuation rating of 1 / 10 to EXAGEN INC (XGN). This can be considered as Overvalued.


Can you provide the profitability details for EXAGEN INC?

EXAGEN INC (XGN) has a profitability rating of 2 / 10.


Can you provide the financial health for XGN stock?

The financial health rating of EXAGEN INC (XGN) is 3 / 10.


Can you provide the expected EPS growth for XGN stock?

The Earnings per Share (EPS) of EXAGEN INC (XGN) is expected to grow by 18.32% in the next year.